OCULAR THERAPEUTIX, INC Increase (Decrease) in Restricted Cash
OCULAR THERAPEUTIX, INC (OCUL) reported Increase (Decrease) in Restricted Cash of -$114.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCash · last filed 2018-03-08
- OCULAR THERAPEUTIX, INC increase (decrease) in restricted cash for the quarter ending 2016-12-31 was $0.00.
- OCULAR THERAPEUTIX, INC increase (decrease) in restricted cash for the quarter ending 2016-09-30 was $0.00.
- OCULAR THERAPEUTIX, INC increase (decrease) in restricted cash for fiscal 2017 was -$114.00K, a 107.60% decline from fiscal 2016.
- OCULAR THERAPEUTIX, INC increase (decrease) in restricted cash for fiscal 2016 was $1.50M.
- OCULAR THERAPEUTIX, INC increase (decrease) in restricted cash for fiscal 2015 was -$60.00K.
| Period end | Increase (Decrease) in Restricted Cash 3 month | Increase (Decrease) in Restricted Cash 6 month | Increase (Decrease) in Restricted Cash 9 month | Increase (Decrease) in Restricted Cash 12 month | Increase (Decrease) in Restricted Cash 12 month as first filed |
|---|---|---|---|---|---|
| 2017-12-31 | -$114.00K 10-K · filed 2018-03-08 | ||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $0.00 derived: sum of 2 quarters · filed 2018-03-08 | $1.50M 10-K · filed 2018-03-08 | ||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $1.50M 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | $1.50M 10-Q · filed 2017-08-08 | ||||
| 2015-12-31 | -$60.00K 10-K · filed 2018-03-08 | $60.00K 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |